Consensus Adaptive Biotechnologies Corporation

Stocks

ADPT

US00650F1093

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
24.02 ^USD	-6.10%		-9.32%	+47.91%

09-21	Adaptive Biotechnologies Insider Sold Shares Worth $3,238,004, According to a Recent SEC Filing	MT
09-17	Adaptive Biotechnologies Corporation Announces Update To NCCN Guidelines For Multiple Myeloma, Strengthening MRD Testing Recommendations And Specifically Referencing ClonoSEQ	CI

Evolution of the Average Target: Adaptive Biotechnologies Corporation

Evolution of the Target Price: Adaptive Biotechnologies Corporation

Changes in Analyst Recommendations: Adaptive Biotechnologies Corporation

86050378c92606567f0113a.9sTYh16SDy5k9JP1PIsuD4fL-vUp8quTmsgnz_TebsE.pqyJzDWgPR88kr67eucWYOO4isUZhuLR3aRLtZamV6uavLL0HdUiQVTGwg~baaf4766ea1f76f76159c31695b48f50

Analysts' recommendations: Adaptive Biotechnologies Corporation

05-12	Morgan Stanley Lowers Price Target on Adaptive Biotechnologies to $18 From $21, Keeps Equalweight Rating	MT
12-02	Morgan Stanley Raises Price Target on Adaptive Biotechnologies to $21 From $16, Keeps Equalweight Rating	MT
25-09-30	Guggenheim Initiates Coverage on Adaptive Biotechnologies With Buy Rating, $20 Price Target	MT
25-06-18	Craig-Hallum Initiates Adaptive Biotechnologies at Buy With $15 Price Target	MT
25-03-21	Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8	MT
24-02-15	JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating	MT
23-10-24	Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating	MT
23-10-20	BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating	MT
23-02-16	Morgan Stanley Trims Adaptive Biotechnologies' Price Target to $15 From $16, Maintains Equalweight Rating	MT
23-01-05	Scotiabank Initiates Adaptive Biotechnologies at Sector Outperform Rating With $15 Price Target	MT
23-01-05	Scotiabank Initiates Adaptive Biotechnologies at Sector Outperform With $15 Price Target	MT
22-12-21	Piper Sandler Upgrades Adaptive Biotechnologies to Overweight From Neutral, Adjusts Price Target to $14 From $7.50	MT
22-11-07	Morgan Stanley Adjusts Price Target on Adaptive Biotechnologies to $16 From $17, Maintains Equalweight Rating	MT
22-10-26	Piper Sandler Adjusts Price Target on Adaptive Biotechnologies to $7.50 From $12, Maintains Neutral Rating	MT
22-08-25	Credit Suisse Initiates Adaptive Biotechnologies at Underperform with $8 Price Target	MT
22-08-25	Credit Suisse Initiates Coverage of 20 Companies in Life Science Tools, Services, Diagnostics Sectors; Outperform-Rated Bio-Rad, IQVIA, Bipo-Techne, Natera Named Top Picks	MT
22-08-18	Piper Sandler Increases Price Target on Adaptive Biotechnologies to $12 From $7.50, Reiterates Neutral Rating	MT
22-08-04	BTIG Adjusts Price Target for Adaptive Biotechnologies to $17 From $25, Maintains Buy Rating	MT
22-06-03	Piper Sandler Starts Adaptive Biotechnologies at Neutral With $7.50 Price Target	MT
22-05-24	Goldman Sachs Adjusts Adaptive Biotechnologies' Price Target to $10 from $14, Keeps Neutral Rating	MT
22-02-16	Goldman Sachs Adjusts Adaptive Biotechnologies' Price Target to $21 from $54, Maintains Neutral Rating	MT
22-02-16	JPMorgan Adjusts Adaptive Biotechnologies' Price Target to $50 from $75, Maintains Overweight Rating	MT
22-02-16	BTIG Adjusts Adaptive Biotechnologies' Price Target to $30 from $35, Maintains Buy Rating	MT
22-02-15	Morgan Stanley Adjusts Adaptive Biotechnologies Price Target to $27 From $46, Maintains Equalweight Rating	MT
22-01-11	BTIG Adjusts Adaptive Biotechnologies' Price Target to $45 From $55; Buy Rating Kept	MT

More recommendations

Bio Diagnostics & Testing

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ADAPTIVE BIOTECHNOLOGIES CORPORATION					+24.12%
	WUXI APPTEC CO., LTD.					+32.97%
	LONZA GROUP AG					+14.74%
	ARGENX SE					+38.45%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+8.87%
	Average					+25.72%
	Weighted average by Cap.					+26.73%